New approaches in the treatment of metastatic transitional-cell cancer of the bladder

World Journal of Urology

Volumn 15, Issue 2, 1997, Pages 139-143

  Corral, David A ^a   Logothetis, Christopher J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOPOIETIC GROWTH FACTOR; RECOMBINANT PROTEIN;

BLADDER TUMOR; GENE THERAPY; HUMAN; METASTASIS; METHODOLOGY; ONCOLOGY; REVIEW; TRANSITIONAL CELL CARCINOMA; UROLOGY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; GENE THERAPY; HEMATOPOIETIC CELL GROWTH FACTORS; HUMANS; MEDICAL ONCOLOGY; RECOMBINANT PROTEINS; URINARY BLADDER NEOPLASMS; UROLOGY;

EID: 0030626586     PISSN: 07244983     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02201986     Document Type: Article

References (28)

1. Boccardo F, Pace M, Guarneri D, Canobbio L, Curotto A. Martorana G (1994) Carboplatin, methotrexate and vinblastine in the treatment of patients with advanced urothelial cancer. Cancer 73: 1932-1936
2. Connor JP, Oison CA, Benson MC, Rapoport F. Sawczuk IS (1989) Long term follow-up in patients treated with methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: Cause for concern. Urology 24: 353-356
3. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E (1993) Regression of bladders tumors in mice treated with interleukin 2 gene modified tumor cells. J Exp Med 177: 11271134
4. Crawford ED, Saiers JH, Baker LH, Costanzi JH, Bukowski RM (1991) Gallium nitrate in advanced bladder carcinoma: Southwest Oncology Group study. Urology 28: 355-357
5. De Wit R, Kaye SB, Roberts JT, Stoter G, Scott J, Verweij J (1993) Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 67: 388-390
6. Dimopoulos MA, Finn L, Logothetis CJ (1994) Pattern of failure and survival of patients with metastatic urothelial tumors relapsing after cis-platinum-based chemotherapy. J Urol 151: 598-601
7. Einhorn LH, Roth BJ, Ansari R, Dreicer R, Gonin R, Loehrer PJ (1994) Phase II trial of vinblastine, ifosfamide, and gallium combination chemotherapy in metastatic urothelial carcinoma. J Clin Oncol 12: 2271 -2276
8. Esrig D. Elmajian D. Groshen S, Freeman JA, Stein JP. Chen SC. Nichols PW. Skinner DG. Jones PA. Cote RJ (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264
9. Gabrilove JL. Jakubowski A. Scher H, Sternberg C, Wong G, Grous J. Yagoda A. Fain K. Moore MAS. Clarkson B. Oettgen HF. Alton K. Weite K. Souza L (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318: 1414-1422
10. Loehrer PJ Sr. Einhorn LH. Elson PJ, Crawford ED. Kuebler P. Tannock I. Raghavan D, Stuart-Harris R. Sarosdy MF. Löwe BA. Blumenstein B. Trump D (1992) A randomized comparison of cisplatin alone or in combination with mcthotrexate. vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 10: 1066-1073
11. Logothetis CJ. Dexeus FH. Finn L, Sella A, Amato RJ. Ayala AG. Kilbourn RG (1990) A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 8: 1050-1055
12. Logothetis CJ. Dexeus FH. Sella A. Amato RJ, Kilbourn RG. Finn L. Gutterman JLJ (1990) Escalated therapy for refractory urothelial tumors: methotrexate-vinblastine-doxorubicin-cisplatin plus unglycosylated recombinant human granulocytemacrophage colony-stimulating factor. J Natl Cancer Inst 82: 667-672
13. Logothetis CJ. Finn L. Smith T, Kilbourn RG. Ellerhorst JA. Zukiwski AA. Sella A. Tu SM. Amato RJ (1995) Escalated MVAC with or without recombinant human granulocytemacrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial. J Clin Oncol 13: 2272-2277
14. Mahjoubi M. Kattan J. Ghosn M, Droz JP. Philippot I. Herait P (1992) Phase II trial of pirarubicin in the treatment of advanced bladder cancer. Int New Drugs 10: 317-321
15. Meyers FJ, Blumenstein B, Crawford ED, Hynes HE, Montie JE. Taylor SA, Grossman HB. Natale RB (1992) Combination cisplatin and dichloromethotrexate in patients with advanced bladder cancer. Phase 2. A Southwest Oncology Group study. J Urol 148: 52-54
16. Mickisch GH, Schroeder FH (1994) From laboratory expertise to clinical practice: multidrug-resistance-based gene therapy becomes available for urologists. World J Urol 12: 104-111
17. Morris BD. Drazan KE. Csete ME, Werthman PE, Bree MP van. Rosenthal JT, Shakes A (1994) Adenoviral-mediated gene transfer to bladder in vivo. J Urol 152: 506-509
18. Niijima T (1986) Phase II collaborative study of (2"R) 4'-0tetrahydropyramyladriamycin (THP) for urological malignancies: urological cooperative study group of THP-ADM. Jpn J Cancer Chemother 13: 224-231
19. Pollera CF. Ceribelli A, Crecco M. Calabresi F (1994) Weekly gemcytabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 5: 182-184
20. Raabe NK. Fossa SD, Paro G (1989) Phase II study of carboplatin in locally advanced and metastatic transitional cell carcinoma of the urinary bladder. Br J Urol 64: 604-607
21. Roth BJ (1995) Preliminary experience with paclitaxel in advanced bladder cancer. Semin Oncol 22: 1-5
22. Roth B. Dreicer R. Einhorn LH. Neuberg D. Johnson DH, Smoth JL: . Hudes OR. Schultz SM. Loehrer PJ (1994) Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 12: 2264-2270
23. Saito S. Bannerji R. Gansbacher B, Rosenthal FM. Romanenko P. Heston WDW, Fair WR, Gilboa E (1994) Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Cancer Res 54: 3516-3520
24. Seidman AD, Scher HI, Heinemann MH, Bajorin DF. Sternberg CN. Dershaw DD. Silverberg M. Bosl GJ (1991) Continuous infusion gallium nitrate for patients with advanced refractory urothelial tract tumors. Cancer 68: 2561-2565
25. Seligman PA. Crawford ED (1991) Treatment of advanced transitional cell carcinoma of the bladder with continuous-infusion gallium nitrate. J Natl Cancer Inst 83: 1582-1584
26. Sola C. Mallafre J. Mendoza Solorzano E, Segarra A, Daniels M. Vinolas N, Alcaraz A, Sole M. Alvarez R. Biete A. Estape J (1993) Carboplatin. methotrexate. vinblastine and epirubicin (Carbo-MVE) for transitional cell bladder carcinoma. Ann Oncol 4: 313-316
27. Sternberg CN, Yagoda A. Scher HI. Watson RC, Herr HW, Morse MJ. Sogani PC. Vaughan ED Jr, Bander N. Weiselberg ER. Geller N. Hollander PS, Eipperman R, Fair WR, Whitmore WF Jr (1988) M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 139: 461169
28. Witte RS. Elson P. Khandakar J, Trump DL (!994) An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 73: 688-691